

330499-00025

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
: Examiner: NYA  
KAREN JACKSON )  
: Group Art Unit: 1614  
Application No.: 10/752,411 )  
: Confirmation No.: 4891  
Filed: January 7, 2004 )  
: May 4, 2004  
For: METHOD OF TREATMENT )

U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window  
Crystal Plaza Two, Lobby Room 1B03  
Arlington, VA 22202

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the document listed on the enclosed forms PTO/SB/08A and PTO/SB/08B. In accordance with current practice, only copies of the foreign patent documents and the non-patent documents are being provided.

In accordance with 37 CFR § 1.97(b)(3) this Information Disclosure Statement is being filed before the mailing of a first Office Action.


Applicant believes that no fee is required. However, the Commissioner is authorized to charge any fees deemed necessary and to make any refunds to Deposit Account 50-1710.

### CONCLUSION

It is respectfully requested that the below-listed information be considered by the Examiner and that a copy of the enclosed Forms PTO/SB/08A and PTO/SB/08B be returned indicating that such information has been considered.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 625-3500. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



---

Attorney for Applicant  
Robert W. Hahl  
Registration No. 33,893

PATENT ADMINISTRATOR  
KATTEN MUCHIN ZAVIS ROSENMAN  
525 West Monroe Street  
Chicago, Illinois 60661-3693  
Facsimile: (312) 902-1061

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet

1

of

3

**Complete if Known**

Application Number	10/752,411
Filing Date	01/07/2004
First Named Inventor	Karen Jackson
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	330499-00025

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		WO99/18967	04-22-1999	Therapeutics Limited		
		WO03/061632	07-31-2003	Karen Jackson		
		EP 0 517 412	12-09-1992	Merck Sharp & Dohme		
		EP 0 434 364	06-26-1991	Merk & Co Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/752,411		
		Filing Date	January 7, 2004		
		First Named Inventor	Karen Jackson		
		Art Unit	1614		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	3	Attorney Docket Number	330499-00025


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		L. BUENO, Involvement of brain CCK in the adaptation of gut motility to digestive status and stress: A review, J Physiology (1993) vol. 87, pp. 301-306	
		J. FIORAMONTI, et al., Involvement of a CCK-dependent capsaicin-sensitive afferent pathway in the inhibitory effect of pinaverium bromide on the colonic motor response to eating in rats, Fundam Clin Pharmacol 1997;11:231-236	
		C. BEGLINGER, Effect of Cholecystokinin on Gastric Motility in Humans, Annals New York Academy of Sciences, Vol 713, Issue 1, pp. 219-225	
		M. D'AMATO, et al., Cholecystokinin-A receptor antagonists: therapies for gastrointestinal disorders, Exp. Opin. Invest. Drugs (1997) 6(7) pp. 819-836	
		J.G. WETTSTEIN, et al., CCK Antagonists: Pharmacology And Therapeutic Interest, Pharmac. Ther., (1994), vol 62, pp. 267-282	
		WILLIAMS, CYNTHIA et al., Cholecystokinin-induced antinociception is not blocked by CCCK-A or CCCK-B receptor antagonists, Peptides(Terrytown), 18(3) 1997 pp.409-414	
		SINGH, L. et al., Modulation of the in vivo actions of morphine by the mixed CCKA/B receptor antagonist PD 142898, European Journal of Pharmacology, Amsterdam, NL, 307(3) 1996, pp. 283-289	
		C.T. DOURISH et al., The Cholecystokinin Receptor Antagonist Devazepide Enhances Morphine-Induced Respiratory Depression in the Squirrel Monkey, The Journal of Pharmacology and Experimental Therapeutics, vol. 255, No. 3, 1990, pp. 1158-1164	
		JOEL HARDMAN et al., Goodman & Gilman's The Pharmacological basis of Therapeutics, 9th Edition, 1996, pp. 526-529 and 540-545	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/752,411		
		Filing Date	January 7, 2004		
		First Named Inventor	Karen Jackson		
		Art Unit	1614		
		Examiner Name	Not Yet Assigned		
Sheet	3	of	3	Attorney Docket Number	330499-00025

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		SHIPTON, South African J. Anesthesiology & Analgesia, Vol 6, #2, pp. 1-12, 2000	
		CHANG et al., Proc. Natl. acad. Sci. USA, Vol. 83, pp. 4923-26, 1986	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.